—
C+
C+ The full Closelook — membership. Open the C+ overview

Biogen Inc (BIIB) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Biogen Inc

BIIB in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Biogen discovers, develops and sells medicines for neurological, immune and rare conditions, largely outside the AI-linked sectors the diary tracks. Its portfolio includes multiple sclerosis treatments such as Tecfidera and Tysabri, the Alzheimer's drug Leqembi, and biosimilar versions of established antibody therapies. It partners with other drug developers, including Eisai and Ionis, to bring several of these medicines to market. The company is headquartered in Cambridge, Massachusetts.
Where it sits in the stack
Biogen carries no seat in Rubin or Halo, our AI-linked indices, so it sits outside the AI build-out stack the diary maps. It belongs instead to the pharmaceutical sleeve of the wider Closelook universe, tracked for its own sector dynamics rather than any layer of chip or data-centre supply.
Who it is priced against
Closelook has not set a peer group for Biogen; within our universe it sits among large-cap drug makers focused on neurology and immunology. The comparison the market often draws is with Eli Lilly, though the two differ in therapeutic focus and scale.
Why Closelook tracks it
Biogen holds a seat in the S&P 500 but no place in Rubin or Halo, and it does not carry a Closelook score. It does not appear in the diary's regular editions or quotes, since coverage there follows the AI-linked names.
What the diary watches
The diary watches whether Leqembi's uptake and the neurology and rare-disease pipeline shift Biogen's earnings mix over time.

Biogen Inc (BIIB) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BIIB, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 3 analyst actions on the wire · latest: price target by Buy by Stifel After Investor Meeting, 2026-09-10

The Street on this name

Analyst actions and the latest print for BIIB from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Buy by Stifel After Investor Meeting — target 242 Target set to $242 (+12.7% to spot) 2026-09-10
  • Price target RBC Capital — target 260 from 240 Target raised to $260 from $240 (+19.2% to spot) 2026-08-25
  • Initiation Wolfe Research — at Outperform Initiated to Outperform from Outperform 2026-08-18

3 actions on the analyst wire since 2026-08-13: 1 initiation, 2 target changes. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BIIB on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Biogen Inc (BIIB)?

Biogen Inc trades as BIIB on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is BIIB in a Closelook index?

Not currently — Biogen Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does BIIB trade against its moving averages?

Uptrend stack intact: Trades +4.2% vs the 50-day and +13.7% vs the 200-day average, 3% below the 52-week high and +61.8% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Biogen Inc do?

Biogen discovers, develops and sells medicines for neurological, immune and rare conditions, largely outside the AI-linked sectors the diary tracks. Its portfolio includes multiple sclerosis treatments such as Tecfidera and Tysabri, the Alzheimer's drug Leqembi, and biosimilar versions of established antibody therapies. It partners with other drug developers, including Eisai and Ionis, to bring several of these medicines to market. Closelook has not set a peer group for Biogen; within our universe it sits among large-cap drug makers focused on neurology and immunology. The comparison the market often draws is with Eli Lilly, though the two differ in therapeutic focus and scale.

Where does Biogen Inc sit in the AI build-out?

Biogen carries no seat in Rubin or Halo, our AI-linked indices, so it sits outside the AI build-out stack the diary maps. It belongs instead to the pharmaceutical sleeve of the wider Closelook universe, tracked for its own sector dynamics rather than any layer of chip or data-centre supply. Biogen holds a seat in the S&P 500 but no place in Rubin or Halo, and it does not carry a Closelook score. It does not appear in the diary's regular editions or quotes, since coverage there follows the AI-linked names.

What has Wall Street done on Biogen Inc recently?

The most recent analyst action on Biogen Inc on the Closelook wire is a price target by Buy by Stifel After Investor Meeting on 2026-09-10 (target 242). 3 actions on the analyst wire since 2026-08-13: 1 initiation, 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BIIB, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.